ADC Therapeutics (ADCT) Depreciation & Amortization (CF) (2023 - 2025)
ADC Therapeutics (ADCT) posted quarterly Depreciation & Amortization (CF) of $362000.0 for Q2 2025, up 11.04% year-on-year from $326000.0 in Q2 2024, and up 5.85% on a QoQ basis from $342000.0 in Q1 2025.
ADC Therapeutics (ADCT) Depreciation & Amortization (CF) (2023 - 2025) Analysis & Trends
ADC Therapeutics (ADCT) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $362000.0 the latest figure, recorded in Q2 2025.
- Quarterly Depreciation & Amortization (CF) rose 11.04% year-over-year to $362000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $362000.0 (down 73.09% YoY) and the FY2025 annual result came in at $705000.0, down 47.15% from the prior year.
- Depreciation & Amortization (CF) rose to $362000.0 in Q2 2025 per ADCT's latest filing, from $342000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for ADCT reached as high as $362000.0 in Q2 2025 and fell as low as $263000.0 in Q1 2023.
- A 3-year average of $322500.0 and a median of $333000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The largest YoY upside for Depreciation & Amortization (CF) was 25.86% in 2024 against a maximum downside of 1.79% in 2024.
- Year by year, Depreciation & Amortization (CF) stood at $335000.0 in 2023, then advanced by 1.79% to $341000.0 in 2024, then gained by 6.16% to $362000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $362000.0, $342000.0, and $341000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 362,000.00 |
| Jun 30, 2025 | 362,000.00 |
| Mar 31, 2025 | 342,000.00 |
| Mar 31, 2025 | 342,000.00 |
| Dec 31, 2024 | 341,000.00 |
| Dec 31, 2024 | 341,000.00 |
| Sep 30, 2024 | 336,000.00 |
| Sep 30, 2024 | 336,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Mar 31, 2024 | 331,000.00 |
| Mar 31, 2024 | 331,000.00 |
| Dec 31, 2023 | 335,000.00 |
| Dec 31, 2023 | 335,000.00 |
| Sep 30, 2023 | 316,000.00 |
| Sep 30, 2023 | 316,000.00 |
| Jun 30, 2023 | 273,000.00 |
| Jun 30, 2023 | 273,000.00 |
| Mar 31, 2023 | 263,000.00 |
| Mar 31, 2023 | 263,000.00 |